Stay updated on Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.
Latest updates to the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page
- Check6 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.3%
- Check13 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference4%
- Check20 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference4%
- Check28 days agoChange DetectedNew content was added on September 5, 2024, following the previous deletions on July 29, 2024.SummaryDifference0.7%
- Check35 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3, indicating a new release.SummaryDifference0.3%
- Check56 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.3%
Stay in the know with updates to Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab/Tremelumab ± Lenvatinib +TACE in HCC Clinical Trial page.